Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
STOK logo STOK
Upturn stock ratingUpturn stock rating
STOK logo

Stoke Therapeutics Inc (STOK)

Upturn stock ratingUpturn stock rating
$11.35
Last Close (24-hour delay)
Profit since last BUY16.29%
upturn advisory
Consider higher Upturn Star rating
BUY since 45 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: STOK (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

10 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $22.38

1 Year Target Price $22.38

Analysts Price Target For last 52 week
$22.38Target price
Low$5.35
Current$11.35
high$16.15

Analysis of Past Performance

Type Stock
Historic Profit -21.67%
Avg. Invested days 29
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 634.96M USD
Price to earnings Ratio 14.18
1Y Target Price 22.38
Price to earnings Ratio 14.18
1Y Target Price 22.38
Volume (30-day avg) 10
Beta 1.1
52 Weeks Range 5.35 - 16.15
Updated Date 06/30/2025
52 Weeks Range 5.35 - 16.15
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.82

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 26.33%
Operating Margin (TTM) 70.15%

Management Effectiveness

Return on Assets (TTM) 7.81%
Return on Equity (TTM) 20.5%

Valuation

Trailing PE 14.18
Forward PE -
Enterprise Value 279443256
Price to Sales(TTM) 3.33
Enterprise Value 279443256
Price to Sales(TTM) 3.33
Enterprise Value to Revenue 1.46
Enterprise Value to EBITDA 6.93
Shares Outstanding 54596900
Shares Floating 38779649
Shares Outstanding 54596900
Shares Floating 38779649
Percent Insiders 4.58
Percent Institutions 110.89

Analyst Ratings

Rating 4
Target Price 22.38
Buy 2
Strong Buy 7
Buy 2
Strong Buy 7
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Stoke Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Stoke Therapeutics Inc. was founded in 2014. The company focuses on developing antisense oligonucleotide (ASO) medicines to treat severe genetic diseases by upregulating protein expression. They went public in 2019. Significant milestones include advancing their lead candidate, STK-001, into clinical trials for Dravet syndrome and developing their TANGO platform for identifying druggable targets.

business area logo Core Business Areas

  • RNA-Targeting Medicines: Focuses on developing RNA-targeting therapies to address the underlying cause of genetic diseases.
  • TANGO Platform: Utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to identify and validate targets for ASO-mediated upregulation.
  • Clinical Development: Conducts clinical trials to evaluate the safety and efficacy of its therapeutic candidates.

leadership logo Leadership and Structure

The leadership team is headed by Edward M. Kaye, MD, as CEO. The company has a scientific advisory board with experts in RNA biology and drug development. Stoke is structured with departments dedicated to research, clinical development, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • STK-001: An antisense oligonucleotide being developed for the treatment of Dravet syndrome. It aims to increase the expression of the SCN1A protein. Currently in clinical development. Market share is not applicable, as it is still in development. Competitors in Dravet syndrome treatment include Zogenix (acquired by UCB), GW Pharmaceuticals (acquired by Jazz Pharmaceuticals), and Biocodex with treatments focusing on symptom management.

Market Dynamics

industry overview logo Industry Overview

The industry is the RNA therapeutics market, characterized by rapid growth and innovation, with increased investment and regulatory approvals. Driven by advances in understanding RNA biology and delivery technologies.

Positioning

Stoke is positioned as a leader in developing ASO-based therapies for genetic diseases, particularly focusing on upregulating gene expression. Their TANGO platform gives them a competitive edge in target discovery.

Total Addressable Market (TAM)

The RNA therapeutics market is projected to reach billions of dollars. Stoke's initial focus on Dravet syndrome represents a significant market opportunity, with potential expansion to other genetic diseases.

Upturn SWOT Analysis

Strengths

  • Novel TANGO platform
  • Focus on underserved genetic diseases
  • Strong intellectual property position
  • Experienced leadership team

Weaknesses

  • Reliance on a single lead candidate
  • High R&D expenses
  • Clinical trial risks
  • No currently marketed products

Opportunities

  • Expanding the TANGO platform to new targets
  • Partnerships and collaborations
  • Positive clinical trial results
  • Regulatory approvals

Threats

  • Competition from other RNA therapeutics companies
  • Clinical trial failures
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • IONS
  • MRNA
  • CRSP

Competitive Landscape

Stoke's advantage lies in its TANGO platform and focus on upregulating gene expression. Compared to larger companies like Ionis and Moderna, Stoke is a smaller player with a narrower focus. The competitive landscape is crowded but rapidly growing.

Growth Trajectory and Initiatives

Historical Growth: Growth is primarily driven by the advancement of their clinical programs and the expansion of the TANGO platform. Stock performance varies widely depending on clinical trial results.

Future Projections: Future growth depends on successful clinical trials and regulatory approvals for STK-001 and other pipeline candidates. Analyst estimates vary depending on the probability of success for these programs.

Recent Initiatives: Recent initiatives include advancing STK-001 in clinical trials, expanding the TANGO platform, and forging strategic partnerships.

Summary

Stoke Therapeutics is a clinical-stage biotechnology company with a novel platform for addressing genetic diseases by upregulating gene expression. Its lead candidate, STK-001, targets Dravet syndrome and is currently in clinical trials. The company's success hinges on the outcome of these trials and its ability to expand its pipeline. Stoke's financial health and clinical trial execution will be critical factors for its future growth. They need to look out for competition from larger companies with marketed products.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Stoke Therapeutics Inc. website
  • SEC filings
  • Analyst reports (e.g., from Yahoo Finance, Bloomberg)

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market share data is based on general industry reports and may not be specific to Stoke's particular segment. Clinical trial outcomes are inherently uncertain.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Stoke Therapeutics Inc

Exchange NASDAQ
Headquaters Bedford, MA, United States
IPO Launch date 2019-06-19
Interim CEO & Director Mr. Ian F. Smith A.C.A., C.P.A.
Sector Healthcare
Industry Biotechnology
Full time employees 128
Full time employees 128

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.